Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
InflaRx ( (IFRX) ) has provided an announcement.
On May 4, 2026, InflaRx reported new preclinical data showing that its investigational C5aR1 inhibitor izicopan generates minimal reactive metabolites in human liver microsomes, suggesting a low level of bioactivation in this in vitro assay. Reactive metabolite formation is a commonly used early indicator of potential bioactivation-related safety risk in drug development, so these findings add to the compound’s emerging safety and differentiation profile.
In a head-to-head glutathione trapping assay, izicopan produced far fewer reactive conjugates than avacopan, a marketed first-in-class C5aR1 inhibitor for ANCA-associated vasculitis, with differences exceeding 100-fold at early time points and remaining about tenfold at later points. While InflaRx cautioned that in vitro results do not directly predict clinical outcomes, the data, combined with prior tolerability, pharmacodynamic and Phase 2a efficacy signals in hidradenitis suppurativa and chronic spontaneous urticaria, bolster investor expectations that izicopan may offer a best-in-class profile within the C5aR inhibitor class.
The new metabolite findings complement earlier evidence that izicopan does not inhibit CYP3A4 and has shown no safety signals of concern in first-in-human and early-stage trials across a wide oral dose range. This integrated safety and mechanistic package could strengthen InflaRx’s competitive positioning in complement-targeted therapies and support future partnering or regulatory strategies as the program advances through later-stage development.
The most recent analyst rating on (IFRX) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on InflaRx stock, see the IFRX Stock Forecast page.
Spark’s Take on IFRX Stock
According to Spark, TipRanks’ AI Analyst, IFRX is a Neutral.
The score is held back primarily by very weak financial performance (minimal/declining revenue, persistent losses, and ongoing cash burn), partially offset by a relatively low-debt balance sheet. Technicals are supportive due to strong upward momentum, but overbought signals add near-term risk, while valuation is difficult to support given negative earnings and no dividend data.
To see Spark’s full report on IFRX stock, click here.
More about InflaRx
InflaRx N.V., based in Germany and listed on Nasdaq, is a biopharmaceutical company developing anti-inflammatory drugs that target the complement system, particularly the inflammatory mediator C5a and its receptor C5aR. Its lead oral small-molecule program, izicopan, is being advanced for multiple inflammatory diseases, alongside vilobelimab, an intravenous anti-C5a monoclonal antibody with demonstrated clinical activity.
The company leverages proprietary anti-C5a and anti-C5aR technologies to create highly specific inhibitors aimed at complement-mediated immunological and inflammatory conditions. InflaRx’s development portfolio includes clinical-stage programs in hidradenitis suppurativa and other indications, supported by operations in Jena and Munich, Germany, and Ann Arbor, Michigan, USA.
Average Trading Volume: 727,292
Technical Sentiment Signal: Buy
Current Market Cap: $151.8M
For an in-depth examination of IFRX stock, go to TipRanks’ Overview page.